News | June 13, 2009

Lantheus to Receive LEU-derived Mo-99 from Australian Nuclear Science

June 13, 2009 - Lantheus will be the first company to be able to offer Technetium-99 (Tc99m) derived from LEU to the U.S. market.

The company says it is committed to ensuring reliable supply and global access to Tc99m, the medical isotope used in approximately 80 percent of all nuclear medicine procedures. Lantheus, together with ANSTO, is working closely with the FDA and Health Canada to achieve the necessary LEU Mo-99 approvals for the U.S. and Canadian markets.

Low enriched uranium (LEU) is a new and safer option for Mo-99 suppliers that cannot be used in nuclear weapons, therefore eliminating the risk of terrorism threats to LEU reactors.

Lantheus’ arrangement with ANSTO emphasizes Lantheus’ ongoing commitment to investing in a supply chain diversification
strategy and providing new solutions to addressing the limited and fragile global Mo-99 supply chain, as evidenced by the current
NRU reactor shutdown in Canada. Without adequate supply of Mo-99, crucial imaging tests that can diagnose life-threatening
conditions such as heart disease and cancer must be canceled or postponed. This arrangement marks another step in Lantheus’
supply chain diversification strategy. In May 2009, Lantheus signed an agreement with NTP Radioisotopes (Pty) Ltd., a subsidiary
of the South African Nuclear Energy Corporation (NECSA), to manufacture and supply Lantheus with an ongoing volume of
Mo-99.

With only a few global suppliers of Mo-99, aging reactors will continue to need more frequent maintenance and repairs. In addition, as the healthcare industry faces an aging population, and the demand for diagnostic services continues to rise, the need for a consistent, reliable supply of Mo-99 has become increasingly critical.

For more information: www.lantheus.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Overlay Init